Ignite Creation Date:
2024-05-06 @ 4:19 PM
Last Modification Date:
2024-10-26 @ 2:08 PM
Study NCT ID:
NCT04947501
Status:
RECRUITING
Last Update Posted:
2024-06-11
First Post:
2021-06-23
Brief Title:
A Study of N9 Chemotherapy in Children with Neuroblastoma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
N9 Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk Neuroblastoma
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to find out whether N9 is a safe and effective treatment for children with neuroblastoma N9 includes 3 different combinations of chemotherapy drugs that are given at different times - Cyclophosphamide topotecan and vincristine CTV Ifosfamide carboplatin and etoposide ICE Cyclophosphamide doxorubicin and vincristine CDV
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None